No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MOH240719C300000
- 9.00
- +8.22+1053.85%
15min DelayClose Jul 16 16:00 ET
9.00High4.40Low
4.40Open0.78Pre Close161 Volume75 Open Interest300.00Strike Price98.67KTurnover41.10%IV0.54%PremiumJul 19, 2024Expiry Date7.33Intrinsic Value100Multiplier2DDays to Expiry1.67Extrinsic Value100Contract SizeAmericanOptions Type0.7613Delta0.0285Gamma34.15Leverage Ratio-0.6874Theta0.0167Rho26.00Eff Leverage0.0820Vega
Intraday
- 5D
- Daily
News
Molina Healthcare's (NYSE:MOH) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
While Molina Healthcare, Inc. (NYSE:MOH) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. But
Molina Healthcare Up Over 5%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk
Molina Healthcare, Inc. (MOH) is currently at $299.68, up $15.71 or 5.53% --Would be highest close since June 27, 2024, when it closed at $302.83 --On pace for largest percent increase since April 27,
Express News | Shares of Health Insurers Are Trading Higher in Sympathy With UnitedHealth, Which Gained Following Strong Q2 Earnings
Express News | Centene Shares Rise 2.1%, Cigna Group Shares up 1.3%, CVS Health Shares up About 1%
Express News | Humana Shares up 3.6%, Elevance Health Shares up 2.3%, Molina Shares up 2.1%
Key Takeaways From Molina Healthcare Analyst Ratings
8 analysts have expressed a variety of opinions on Molina Healthcare (NYSE:MOH) over the past quarter, offering a diverse set of opinions from bullish to bearish.In the table below, you'll find a
Comments
The 13F filing for the hedge fund led by the late Jim Simons (RIP) just dropped and we got you covered
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
+1
18
RECAP
April rain better mean the stock market stops the pain by May: the market declined Tuesday, punctuated by the fall of fan favorite Tesla. The EV maker made less EV's than last year and dropped nearly 5%.
Stocks closed lower, the $S&P 500 Index(.SPX.US$ was recently down about 0.72%. $NASDAQ 100 Index(.NDX.US$ fell about 0.94%. $Dow Jones Industrial Average(.DJI.US$ fell 1%.
MACRO
Job openings recorded by JOLTS were just shy of expectations...
April rain better mean the stock market stops the pain by May: the market declined Tuesday, punctuated by the fall of fan favorite Tesla. The EV maker made less EV's than last year and dropped nearly 5%.
Stocks closed lower, the $S&P 500 Index(.SPX.US$ was recently down about 0.72%. $NASDAQ 100 Index(.NDX.US$ fell about 0.94%. $Dow Jones Industrial Average(.DJI.US$ fell 1%.
MACRO
Job openings recorded by JOLTS were just shy of expectations...
42
4
Recent insider selling at Molina Healthcare may hint at insiders believing the shares are overpriced. Despite profitability and profit growth, the absence of insider buying and recent selling could caution investors.
Analysts' sentiment remains steady post latest results, with a minor rise in revenue forecasts. Despite EPS missing estimates, earnings continue to be the value driver. Molina Healthcare's revenue growth rate is expected to surpass the industry.
1
Molina Healthcare's high P/E ratio is justified by its strong forecast growth, surpassing the wider market. Investors see insignificant potential for earnings deterioration, hence a lower P/E ratio isn't warranted. Share price drop in near future is unlikely.
Read more